"Doxazosin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
| Descriptor ID |
D017292
|
| MeSH Number(s) |
D03.633.100.786.750.200
|
| Concept/Terms |
Cardura- Cardura
- Cardular
- Zoxan
- Carduran
Doxazosin Mesylate- Doxazosin Mesylate
- Mesylate, Doxazosin
- 1 (4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)piperazine
Doxazosin-ratiopharm- Doxazosin-ratiopharm
- Doxazosin ratiopharm
- ratio-Doxazosin
- ratio Doxazosin
- Doxazosina Ratiopharm
- Ratiopharm, Doxazosina
|
Below are MeSH descriptors whose meaning is more general than "Doxazosin".
Below are MeSH descriptors whose meaning is more specific than "Doxazosin".
This graph shows the total number of publications written about "Doxazosin" by people in this website by year, and whether "Doxazosin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Doxazosin" by people in Profiles.
-
Spironolactone for resistant hypertension--hard to resist? Lancet. 2015 Nov 21; 386(10008):2032-2034.
-
Use of novel urodynamic parameters, detrusor contraction duration and detrusor contraction index, in men with lower urinary tract symptoms. Tech Urol. 1998 Sep; 4(3):136-40.
-
Doxazosin in men with lower urinary tract symptoms: urodynamic evaluation at 15 months. Urology. 1997 Aug; 50(2):229-33.
-
Ambulatory urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin. Tech Urol. 1997; 3(3):164-7.
-
An observational urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin. Urology. 1996 Jun; 47(6):840-4.